Get the Stockscreener App
1.41
5.37%
-0.08
After Hours:
1.42
0.01
+0.71%
Geron Corp stock is traded at $1.41, with a volume of 14.43M.
It is down -5.37% in the last 24 hours and down -7.24% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$1.49
Open:
$1.485
24h Volume:
14.43M
Relative Volume:
1.19
Market Cap:
$1.02B
Revenue:
$29.48M
Net Income/Loss:
$-201.19M
P/E Ratio:
-4.4063
EPS:
-0.32
Net Cash Flow:
$-216.50M
1W Performance:
-0.70%
1M Performance:
-7.24%
6M Performance:
-60.17%
1Y Performance:
-66.75%
1-Day Range:
$1.3646
$1.485
1-Week Range:
$1.3646
$1.57
52-Week Range:
$1.17
$5.06
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.41 | 1.02B | 29.48M | -201.19M | -216.50M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral |
| Feb-26-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
With 65% institutional ownership, Geron Corporation (NASDAQ:GERN) is a favorite amongst the big guns - Yahoo Finance
Geron: A Tough First Year For Rytelo, But Not Yet Time To Sell (Downgrade) (NASDAQ:GERN) - Seeking Alpha
Geron Q1 2025 slides: RYTELO growth plans amid revenue challenges - Investing.com
Geron Q1 2025 slides: RYTELO growth plans amid revenue challenges By Investing.com - Investing.com Canada
Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights - mx.advfn.com
Class Action Filed Against Geron Corporation (GERN)May 12, 2025 Deadline to JoinContact The Gross Law Firm - mx.advfn.com
Conservative Vision Of A Positive Future For Geron (NASDAQ:GERN) - Seeking Alpha
Nuveen Asset Management LLC Purchases 14,657 Shares of Geron Co. (NASDAQ:GERN) - Defense World
Geron showcases RYTELO benefits at oncology meetings By Investing.com - Investing.com South Africa
Geron’s SWOT analysis: oncology firm’s stock faces growth hurdles By Investing.com - Investing.com South Africa
Geron showcases RYTELO benefits at oncology meetings - Investing.com
Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program - Yahoo Finance
Geron’s SWOT analysis: oncology firm’s stock faces growth hurdles - Investing.com
Geron Corp stockholders approve equity plan amendments By Investing.com - Investing.com India
Geron Corp stockholders approve equity plan amendments - Investing.com
BNP Paribas Financial Markets Decreases Stock Holdings in Geron Co. (NASDAQ:GERN) - Defense World
25,148 Shares in Geron Co. (NASDAQ:GERN) Purchased by Lazard Asset Management LLC - Defense World
Geron Co. (NASDAQ:GERN) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Bank of America Corp DE Boosts Stock Position in Geron Co. (NASDAQ:GERN) - Defense World
Ameriprise Financial Inc. Buys 247,018 Shares of Geron Co. (NASDAQ:GERN) - Defense World
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GERN Stock News - GuruFocus
Geron Grants $522K Worth of Stock Options and RSUs: New Employee Compensation Details Revealed - Stock Titan
Stifel Financial Corp Increases Position in Geron Co. (NASDAQ:GERN) - Defense World
Geron Corp Stock (GERN): Demand Recovery on the Rise - Value The Markets
Northern Trust Corp Has $19.76 Million Stake in Geron Co. (NASDAQ:GERN) - Defense World
Why Geron Corporation (GERN) Is The Best Low Priced Biotech Stock to Buy Now - Insider Monkey
Geron Corporation Investors: Please contact the Portnoy Law - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - Business Wire
GERN Investors are Reminded of an Opportunity to Lead Geron Corp - GuruFocus
10 Best Low Priced Biotech Stocks to Buy Now - Insider Monkey
GERN Investors are Reminded of an Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm - Benzinga
Geron outlines strategies to boost RYTELO adoption and anticipates Phase III myelofibrosis trial results in 2026 - MSN
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron LawsuitGERN - Stockhouse
Faruqi & Faruqi Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN - GlobeNewswire
Research Analysts Set Expectations for Geron FY2028 Earnings - Defense World
Analysts Have Lowered Expectations For Geron Corporation (NASDAQ:GERN) After Its Latest Results - simplywall.st
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 3D Systems Corporation - GlobeNewswire Inc.
Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade) - Seeking Alpha
Lost Money on Geron Corporation (GERN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Stockhouse
Geron slips as Scotiabank downgrades on sales challenges for blood cancer drug - MSN
Geron (GERN) Faces Downgrade Amid Rytelo Rollout Concerns - GuruFocus
Geron stock is downgraded at Scotiabank (GERN:NASDAQ) - Seeking Alpha
Geron (GERN) Price Target Reduced by Wedbush Amid Uptake Challen - GuruFocus
Geron (GERN) Experiences Notable Downgrade from Scotiabank | GER - GuruFocus
Geron Corporation (NASDAQ:GERN) Q1 2025 Earnings Call Transcript - Insider Monkey
Geron (GERN) Experiences Notable Downgrade from Scotiabank | GERN Stock News - GuruFocus
Geron (GERN) Faces Downgrade Amid Rytelo Launch Challenges | GERN Stock News - GuruFocus
Class Action Filed Against Geron Corporation (GERN) Seeking Recovery for InvestorsContact Levi & Korsinsky - Stockhouse
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Geron Corporation(GERN) Shareholders - PR Newswire
Geron Corp (GERN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and Strategic ... - Yahoo Finance
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Geron Corp Stock (GERN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Samuels Scott Alan | EVP, Chief Legal Officer |
Feb 27 '25 |
Buy |
1.61 |
15,000 |
24,150 |
26,682 |
| SCARLETT JOHN A | Chairman, President and CEO |
Feb 27 '25 |
Buy |
1.76 |
12,500 |
22,062 |
12,500 |
| Ziegler James | EVP, Chief Commercial Officer |
Feb 27 '25 |
Buy |
1.60 |
100,000 |
160,000 |
100,000 |
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer |
Jul 08 '24 |
Option Exercise |
1.72 |
674,348 |
1,159,879 |
674,348 |
| GRETHLEIN ANDREW J | EVP, Chief Operating Officer |
Jul 08 '24 |
Sale |
4.56 |
674,348 |
3,073,004 |
0 |
0.78%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):